Stroke candidate to feel brunt of Cytomedix restructure

Cytomedix is to downsize its R&D activities in a renewed focus on profitability, in what is its second reorganization in as many months.

Cytomedix is to downsize its R&D activities in a renewed focus on profitability, in what is its second reorganization in as many months.

As part of its latest initiative, the company's will "substantially conclude" support for the RECOVER-Stroke trial of its adult stem...

More from Dermatological

More from Therapy Areas

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.